About LAKEWOOD-AMEDEX INC
Lakewood Amedex Biotherapeutics is developing a new class of antimicrobial compounds called Bisphosphocin® to address the antibiotic resistance crisis. Their lead compound, Nu-3, targets infected diabetic foot ulcers caused by resistant pathogens.
Development of Bisphosphocin® class of antimicrobial compoundsRapid eradication of bacteria and fungi by depolarizing microbial cell membranes/wallsTargeting multidrug-resistant bacteria and infected diabetic foot ulcers (iDFU)
Is this your company?
Claim LAKEWOOD-AMEDEX INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim LAKEWOOD-AMEDEX INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.